NEWS

For generations, the story of European pharmaceutical competitiveness has been one of stark decline,  providing a harsh lesson in what happens when price controls crowd out innovation. Europe's declining drug approval trajectory is a warning for U.S. policymakers  tempted by most-favored nation drug pricing. The decline has not gone unnoticed in Brussels. Motivated by years of self-inflicted setbacks, European leaders have begun to mount a serious campaign to reclaim the cont

During Rare Disease Week, the Senate Special Committee on Aging held a hearing  focused on the urgent need to strengthen the United States biomedical innovation ecosystem to benefit patients.   Lawmakers, advocates and industry leaders underscored a shared reality: for individuals living with rare and ultra-rare diseases, innovation represents both hope and the possibility of future access to treatment.   This moment calls attention to the scale of unmet medical need and to t

We Work For Health Executive Director Dan Leonard issued the following statement in response to President Trump’s call for the codification of Most Favored Nation price controls during his State of the Union Address.   “Last night, we heard again from the Administration about their plans to lower healthcare costs for American families – an admirable goal that has remained a priority for President Trump. We Work For Health shares the Administration's urgent desire to address t

We Work For Health recently submitted formal comment letters urging the Centers for Medicare & Medicaid Services to reject and withdraw both the Global Benchmark for Efficient Drug Pricing (GLOBE) model for Medicare Part B and the Guarding U.S. Medicare Against Rising Drug Costs (GUARD) model for Medicare Part D.  If implemented, these models will significantly harm American life sciences innovation, the millions of workers whose livelihoods depend on it and the patients thes

According to the FDA's annual report released last month, the agency's Center for Drug Evaluation and Research (CDER) approved 46 novel prescription drugs in 2025 – slightly fewer than in recent years. While America's prescription drug approval process remains the global gold standard, maintaining this leadership position requires urgent attention from policymakers as competitive pressures from abroad intensify.    The United States cannot afford complacency. China is pourin

By: Dan Leonard, Executive Director, We Work For Health Maintaining America’s momentum demands that policymakers resist policies that undermine research and development incentives. Last year marked a transformative moment for the biopharmaceutical sector: the industry committed to nearly $500 billion in domestic investments, an almost 1,500% surge compared to 2024. My organization, We Work For Health, documents where these investments flow on our U.S. Biopharma Investment Wa

Breakthroughs in medicine rarely happen in a single moment. More often, they are the result of years, sometimes decades, of research, experimentation and sustained investment.   In biopharma, this long-term perspective is essential. Treatments that once seemed unimaginable are now reaching patients who never expected to benefit from them in their lifetimes. These advances were made possible because early ideas were given the time, protection and resources needed to develop.  

By: Richard Bagger, Board Member, Center for Medicine in the Public Interest; former New Jersey State Legislator and Chief of Staff to New Jersey Governor Chris Christie.  When government officials propose policies that set prices for life-saving medicines, the idea can sound simple: make prescription drugs more affordable and easier to access. But history, economics, and global experience tell a much different story. Government price controls, including importing other count